Drugs / JTA-004
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT02740231 | Feb 2016 → Apr 2018 | osteoarthritis, knee | Bone Therapeutics S.A | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT04333160 | Mar 2020 → Mar 2021 | osteoarthritis, knee | Bone Therapeutics S.A | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JTA-004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04333160 ↗ |
| Modality | Protein / enzyme biologic | “a novel enhanced protein solution (JTA-004)” PMID 34666767 ↗ Oct 2021 |
| Route | Other | “intra-articular injection of JTA-004” PMID 34666767 ↗ Oct 2021 |